The Global Nanobodies Market Is Estimated To Be Valued At US$ 368.6 Million In 2023 And Is Expected To Exhibit A CAGR Of 24.1%

sachin121

posted on 5 months ago — updated on 1 second ago

60
views

Nanobodies are single-domain antibody fragments derived from heavy-chain antibodies found naturally in Camelidae including camels, dromedaries, alpacas, and llamas.

The Global Nanobodies Market Is Estimated To Be Valued At US$ 368.6 Million In 2023 And Is Expected To Exhibit A CAGR Of 24.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Nanobodies are recombinant versions of single variable domains of camelid heavy-chain antibodies or nanobodies. They have several advantages over conventional antibodies as a result of their small size, stability and solubility, and ability to target 'undruggable' targets. These properties make nanobodies attractive alternatives to monoclonal antibodies for therapeutic and diagnostic applications.

Market key trends:
One of the key trends driving growth in the nanobodies market is their increasing adoption as alternatives to monoclonal antibodies. Given their small size, nanobodies can access epitopes that are cryptic or inaccessible to conventional antibodies. They also have excellent tissue penetration capabilities. As a result, nanobodies are being increasingly explored as potential treatments for various diseases and conditions where access has been challenging with conventional antibodies, such as cancer, neurodegenerative diseases, and viral/bacterial infections. Their ability to target previously ‘undruggable’ epitopes expands the target space for therapeutic intervention.

Segment Analysis

The global Nanobodies Market is segmented based on product type, activity type, application, end-user, and geography. Based on product type, the market is divided into therapeutic nanobodies and research-use nanobodies. Therapeutic nanobodies dominates the market due to the increasing investments in development of nanobody-based therapeutics for various diseases like cancer and infectious diseases.

Based on activity type, the nanobodies market is classified into enzyme inhibition, carrier & transport, catalysis, ligand recognition, immuno-detection, and antibacterial, among others. Ligand recognition dominates the market as nanobodies have high affinity and specificity to target proteins and ligands.

Key Takeaways

The global nanobodies market is expected to witness high growth, exhibiting CAGR of 24.1% over the forecast period of 2022-2030, due to increasing R&D investment in development of nanobody-based therapeutics and diagnostics.

- The market size was valued at US$ 368.6 Million In 2023 and is projected to reach over US$ 2,342.3 Million By 2030.

- Europe dominates the nanobodies market and is expected to grow at a high CAGR during the forecast period. Increasing biotech industry in Germany, France and UK contributing to the market growth in the region.

- Asia Pacific is projected to be the fastest growing regional market owing to rising government funding for R&D in China, India and Japan.

- Key players operating in the nanobodies market are Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., Abcepta Biotech Ltd. Co. These players are focusing on new product launches and strategic collaborations to strengthen their market position.